Clinical Trial

A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma

Name: A Clinical Trial Evaluating Patients With Primary Vitreoretinal Lymphoma — clinical trial record (NCT07402876)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

A prospective, randomized, double-masked, dosing-frequency-controlled, multicenter clinical trial evaluating the safety and activity of intravitreally injected ADX-2191 (methotrexate injection USP) in patients with primary vitreoretinal lymphoma

Trial Details

NCT Number	NCT07402876
Lead Sponsor	Aldeyra Therapeutics, Inc.
Conditions	Primary Vitreoretinal Lymphoma
Enrollment	20 participants
Start Date	2026-02
Primary Completion	2026-12 (estimated)
Study Completion	2026-12 (estimated)
Updated on ClinicalTrials.gov	2026-02-11